Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Abstract P5-02-07: Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis

Arielle J. Medford, Marko Velimirovic, Andrzej Niemierko, Whitney L. Hensing, Andrew A. Davis, Katherine K. Clifton, Jennifer C. Keenan, Charles S. Dai, Lesli A. Kiedrowski, Ami N. Shah, Lorenzo Gerratana, Laura M. Spring, Leif Ellisen, Robert C. Doebele, Massimo Cristofanilli, Aditya Bardia

Cancer Res (2023) 83 (5_Supplement): P5-02-07.

https://doi.org/10.1158/1538-7445.SABCS22-P5-02-07

Published: 01 March 2023

View articletitled, Abstract P5-02-07: Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis

Journal Articles

Abstract P6-10-10: Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan

Francois-Clement Bidard, Diana Bello Roufai, Arielle J. Medford, Vijaya Tirunagaru, Robert C. Doebele, Aditya Bardia

Cancer Res (2023) 83 (5_Supplement): P6-10-10.

https://doi.org/10.1158/1538-7445.SABCS22-P6-10-10

Published: 01 March 2023

View articletitled, Abstract P6-10-10: Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan

Journal Articles

Abstract 1102: Fyn and Src cooperate with ERBB family to drive resistance to crizotinib in ROS1+ and ALK+ NSCLC

Logan C. Tyler, Nan Chen, Anh T. Le, Hala Nijmeh, Liming Bao, Robert C. Doebele

Cancer Res (2022) 82 (12_Supplement): 1102.

https://doi.org/10.1158/1538-7445.AM2022-1102

Published: 15 June 2022

View articletitled, Abstract 1102: Fyn and Src cooperate with ERBB family to drive resistance to crizotinib in ROS1+ and ALK+ NSCLC

Journal Articles

Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double positive NSCLC

Katherine Priest, Anh Le, Dara Aisner, Amanuail Gebregzabheir, Hala Nijmeh, Melanie Mandell, Kurtis Davies, Emily O'Donnell, Robert C. Doebele, Liming Bao, Erin L. Schenk

Cancer Res (2022) 82 (12_Supplement): 5233.

https://doi.org/10.1158/1538-7445.AM2022-5233

Published: 15 June 2022

View articletitled, Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double positive NSCLC

Journal Articles

Abstract 1100: miR205 mediates acquired resistance to ALK inhibition via targeting Mig6 expression and enhancing EGFR signaling

Nan Chen, Robert C. Doebele

Cancer Res (2022) 82 (12_Supplement): 1100.

https://doi.org/10.1158/1538-7445.AM2022-1100

Published: 15 June 2022

View articletitled, Abstract 1100: miR205 mediates acquired resistance to ALK inhibition via targeting Mig6 expression and enhancing EGFR signaling

Journal Articles

Abstract 3984: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

Cancer Res (2022) 82 (12_Supplement): 3984.

https://doi.org/10.1158/1538-7445.AM2022-3984

Published: 15 June 2022

View articletitled, Abstract 3984: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

Journal Articles

Abstract 1103: MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

Logan C. Tyler, Anh T. Le, Hala Nijmeh, Liming Bao, Timothy R. Wilson, Brian Simmons, David Chen, Robert C. Doebele

Cancer Res (2022) 82 (12_Supplement): 1103.

https://doi.org/10.1158/1538-7445.AM2022-1103

Published: 15 June 2022

View articletitled, Abstract 1103: MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

Journal Articles

Abstract CT235: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas

Mrinal M. Gounder, Gary K. Schwartz, Robin L. Jones, Sant P. Chawla, Victoria S. Chua-Alcala, Silvia Stacchiotti, Andrew J. Wagner, Gregory M. Cote, Robert G. Maki, Hanna Kosela-Paterczyk, Dale R. Shepard, Naisargee Shah, Richard Bryce, Robert C. Doebele, Shreyaskumar Patel

Cancer Res (2022) 82 (12_Supplement): CT235.

https://doi.org/10.1158/1538-7445.AM2022-CT235

Published: 15 June 2022

View articletitled, Abstract CT235: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas

Journal Articles

Abstract 1174: Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors

Vijaya G. Tirunagaru, Feng Xu, Robert C. Doebele

Cancer Res (2022) 82 (12_Supplement): 1174.

https://doi.org/10.1158/1538-7445.AM2022-1174

Published: 15 June 2022

View articletitled, Abstract 1174: Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors

Journal Articles

Abstract CT123: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)

Ecaterina I. Dumbrava, Glenn J. Hanna, Gregory M. Cote, Thomas E. Stinchcombe, Melissa L. Johnson, Christopher T. Chen, Siddhartha H. Devarakonda, Naisargee Shah, Feng Xu, Robert C. Doebele, Mrinal M. Gounder

Cancer Res (2022) 82 (12_Supplement): CT123.

https://doi.org/10.1158/1538-7445.AM2022-CT123

Published: 15 June 2022

View articletitled, Abstract CT123: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)

Journal Articles

Abstract 1865: Phosphoproteomic analyses identify EGFR as a critical cooperative kinase for ALK

Nan Chen, Anh T. Le, Andrea E. Doak, Guolin Zhang, Bin Fang, Eric B. Haura, Robert C. Doebele

Cancer Res (2020) 80 (16_Supplement): 1865.

https://doi.org/10.1158/1538-7445.AM2020-1865

Published: 15 August 2020

View articletitled, Abstract 1865: Phosphoproteomic analyses identify EGFR as a critical cooperative kinase for ALK

Journal Articles

Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers

Hui Yu, Shevan Silva, Adriana Estrada-Bernal, Chris Rivard, Fred Hirsch, Maria Abbatista, Jeff Smaill, Robert C. Doebele, Adam Patterson, Avanish Vellanki, Vijaya G. Tirunagaru

Cancer Res (2019) 79 (13_Supplement): 4025.

https://doi.org/10.1158/1538-7445.AM2019-4025

Published: 01 July 2019

View articletitled, Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers

Journal Articles

Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers

Vijaya G. Tirunagaru, Adriana Estrada-Bernal, Hui Yu, Chris Rivard, Fred Hirsch, Matthew Bull, Maria Abbatista, Jeff Smaill, Adam V. Patterson, Robert C. Doebele, Avanish Vellanki

Cancer Res (2019) 79 (13_Supplement): 2202.

https://doi.org/10.1158/1538-7445.AM2019-2202

Published: 01 July 2019

View articletitled, Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers

Journal Articles

Abstract CT192: Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Alexander Drilon, Fabrice Barlesi, Filippo De Braud, Byoung Chul Cho, Myung-Ju Ahn, Salvatore Siena, Matthew G. Krebs, Chia-Chi Lin, Tom John, Daniel SW Tan, Takashi Seto, Rafal Dziadziuszko, Hendrick-Tobias Arkenau, Christian Rolfo, Jürgen Wolf, Chenglin Ye, Todd Riehl, Susan Eng, Robert C. Doebele

Cancer Res (2019) 79 (13_Supplement): CT192.

https://doi.org/10.1158/1538-7445.AM2019-CT192

Published: 01 July 2019

View articletitled, Abstract CT192: Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Journal Articles

Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

Alexander Drilon, Dayong Zhai, Wei Deng, Xin Zhang, Dong Lee, Evan Rogers, Jeffrey Whitten, Zhongdong Huang, Armin Graber, Juliet Liu, Shanna Stopatschinskaja, J. Jean Cui, Dong-Wan Kim, Byoung Chul Cho, Robert C. Doebele, Sai-Hong Ignatius Ou, Jeeyun Lee, Alice T. Shaw

Cancer Res (2019) 79 (13_Supplement): 442.

https://doi.org/10.1158/1538-7445.AM2019-442

Published: 01 July 2019

View articletitled, Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

Journal Articles

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

Dana S. Neel, David V. Allegakoen, Victor Olivas, Manasi K. Mayekar, Golzar Hemmati, Nilanjana Chatterjee, Collin M. Blakely, Caroline E. McCoach, Julia K. Rotow, Anh Le, Niki Karachaliou, Rafael Rosell, Jonathan W. Riess, Robert Nichols, Robert C. Doebele, Trever G. Bivona

Cancer Res (2019) 79 (3): 546–556.

https://doi.org/10.1158/0008-5472.CAN-18-1492

Published: 01 February 2019

View articletitled, Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

Includes: Supplementary data

Journal Articles

Abstract 4766: The Global ROS1 Initiative: A patient-researcher partnership generating open-source, oncogene-driven cancer models and data

Janet Freeman-Daily, Lisa Goldman, Tori Tomalia, The ROS1ders, Christine M. Lovly, Manali I. Patel, Alice T. Shaw, Bonne J. Addario, Guneet Walia, Steven W. Young, Robert C. Doebele

Cancer Res (2018) 78 (13_Supplement): 4766.

https://doi.org/10.1158/1538-7445.AM2018-4766

Published: 01 July 2018

View articletitled, Abstract 4766: The Global ROS1 Initiative: A patient-researcher partnership generating open-source, oncogene-driven cancer models and data

Journal Articles

Abstract 1842: Novel KIF5B-RET+ NSCLC cell lines demonstrate differential responses to RET inhibitors

Laura Schubert, Anh T. Le, Andrea E. Doak, Robert C. Doebele

Cancer Res (2018) 78 (13_Supplement): 1842.

https://doi.org/10.1158/1538-7445.AM2018-1842

Published: 01 July 2018

View articletitled, Abstract 1842: Novel KIF5B-RET+ NSCLC cell lines demonstrate differential responses to RET inhibitors

Journal Articles

Abstract 936: Analysis of cell-free DNA from 32,991 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations

Karen L. Reckamp, Thereasa A. Rich, Young Kwang Chae, Robert C. Doebele, Wade T. Iams, Michael Oh, Victoria M. Raymond, Richard B. Lanman, Thomas E. Stinchcombe, Vivek Subbiah, David R. Trevarthen, Oliver P. Gautschi

Cancer Res (2018) 78 (13_Supplement): 936.

https://doi.org/10.1158/1538-7445.AM2018-936

Published: 01 July 2018

View articletitled, Abstract 936: Analysis of cell-free DNA from 32,991 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations

Journal Articles

Abstract B33: CRISPR/Cas9 generation of Ret and Ntrk1 fusion oncogenes and novel in vitro sgRNA screening method

Laura Schubert, Anh T. Le, Stephen P. Malkoski, Raphael Nemenoff, Robert C. Doebele

Cancer Res (2018) 78 (10_Supplement): B33.

https://doi.org/10.1158/1538-7445.MOUSEMODELS17-B33

Published: 14 May 2018

View articletitled, Abstract B33: CRISPR/Cas9 generation of Ret and Ntrk1 fusion oncogenes and novel in vitro sgRNA screening method

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract P5-02-07: Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis

Abstract P6-10-10: Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan

Abstract 1102: Fyn and Src cooperate with ERBB family to drive resistance to crizotinib in ROS1+ and ALK+ NSCLC

Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double positive NSCLC

Abstract 1100: miR205 mediates acquired resistance to ALK inhibition via targeting Mig6 expression and enhancing EGFR signaling

Abstract 3984: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

Abstract 1103: MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

Abstract CT235: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas

Abstract 1174: Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors

Abstract CT123: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)

Abstract 1865: Phosphoproteomic analyses identify EGFR as a critical cooperative kinase for ALK

Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers

Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers

Abstract CT192: Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

Abstract 4766: The Global ROS1 Initiative: A patient-researcher partnership generating open-source, oncogene-driven cancer models and data

Abstract 1842: Novel KIF5B-RET+ NSCLC cell lines demonstrate differential responses to RET inhibitors

Abstract 936: Analysis of cell-free DNA from 32,991 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations

Abstract B33: CRISPR/Cas9 generation of Ret and Ntrk1 fusion oncogenes and novel in vitro sgRNA screening method

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only